Alumis Inc. announces successful Phase 2 trial results for oral TYK2 inhibitor ESK-001 in plaque psoriasis, with Phase 3 trials planned for H2 2024.
Alumis Inc. presents positive Phase 2 clinical trial data for ESK-001, an oral allosteric TYK2 inhibitor targeting plaque psoriasis. The STRIDE trial met primary and secondary endpoints at all tested doses, and an open-label extension study showed increasing PASI responses and high efficacy rates of 80-90% at the top dose, with a favorable safety profile. Phase 3 trials are planned for H2 2024.
March 09, 2024
4 Articles